St. Francis Hospital Nsambya
Kampala, +256, Uganda
NCT Number: NCT03729089
Study topic:
Predicting fetal outcome using third trimester modified biophysical profile (BPP) scan compared with standard of care; a randomized clinical trial at St. Francis Hospital, Nsambya.
This is an open label randomized clinical trial comparing the third trimester modified biophysical profile done between 34 to 40 weeks with the current standard of care in reducing perinatal mortality at St. Francis Hospital, Nsambya
Objectives of the study:
Broad study objectives:
To evaluate the role of third trimester modified biophysical profile scan in predicting fetal outcome among pregnant mothers at St. Francis Hospital, Nsambya.
Specific study objectives:
* To determine the percentage decline in perinatal mortality following use of third trimester biophysical profile from 34 to 40 weeks at St. Francis Hospital, Nsambya. * To determine if use of third trimester BPP scan improves prediction of perinatal outcome more than the current standard of care at St. Francis Hospital, Nsambya. * To determine the fetal outcome of pregnancies done modified BPP and those who received current standard of care at St. Francis Hospital, Nsambya.
Hypothesis:
The hypothesis of the study is that performing third trimester modified biophysical profile scan between 34 and 40 weeks compared to standard of care is associated with a 16 percent reduction
Looking for future studies?
Notify MeFemale
Interventional
Not applicable
Kampala, +256, Uganda
Randomization:
Eligible participants will be randomly allocated to one of the two study groups (modified biophysical profile scan arm or current standard of care arm) by an independent statistician who will not be involved in data analysis. The independent statistician will generate a randomization register consisting of the sequential study numbers but without the allocated study group. The register will be held at the enrollment clinic and patients who will be eligible for enrollment will be assigned the next available number on the register until the required sample size is reached. The principal investigator will identify a secure room from where opaque envelopes containing the different study arms will be kept. Participants will pick envelopes randomly from the pool of envelopes to obtain the study arm to which they automatically belong.
Blinding:
The study will be open label but only blinding the allocation at study entry.
Randomization concealment
No one including the independent statistician will know the study arm at the point of randomization. Because the intervention is not blinded, the rest of the study team including the principle investigator will get to know the study arm after the women have been randomized.
Sample size:
The use of fetal biophysical profile has been associated with 61 to 79 percent reduction in fetal mortality and morbidity. The incidence of perinatal death (Macerated still birth, Fresh stillbirth & Early neonatal death) in 2016 was 2% of the annual total deliveries, giving a perinatal mortality ratio of 20 per 1000 live birth at St. Francis Hospital Nsambya. The following assumptions will be made in the determination of the minimum sample size; the current standard of care of mothers attending antenatal care at Nsambya Hospital as defined by World health organization (WHO) in 2016 will detect up to 79% of fetal outcome, while performing modified biophysical profile scan proposed in this trial will increase this proportion to 95% at the 5% level of significance, and power of 80. Using a formula for comparing two proportions from Medical statistics book by Betty Kirkwood and Jonathan Sterne, 2003; The minimum sample size , Where this gives an increase in prediction of 16%. V= the Standard normal deviate at 95% Confidence (from Z-statistical tables, V=1.96), U =Standard Normal Deviate at 80% Power (power =1-β) ( from Z-statistical tables, u=0.84). Substituting, = 89.2 women. This gives approximately 90 women in each group and a total sample size of 180 women. Assuming a non-response proportion of 10%, the sample size will be increased by 10% to 198 women (99 in each group).
Data management and handling:
The study data will be entered using Microsoft (MS) access (MS-ACCESS, 2016) and will be double checked and validated before being uploaded into the database. The data entry screens will incorporate a number of range checks and logical skips as appropriate. Data stored in the database will be checked for missing or unusual values (range checks) and checked for consistency within participants. If any such problems are identified the problematic questionnaire will be returned to the clinic for checking and confirmation or correction, as appropriate. The amended version will be returned to the data entrant for correct entry into the database.
Statistical analysis plan:
Participant socio-demographics and other characteristics will be summarized using counts and percentages and by study group, for categorical variables and means and standard deviation for continuous variables. The analysis will be by intention to treat (ITT). I will calculate the mortality rate as the number of death divided by total time of follow up. The mortality will be further stratified by the study group (intervention vs standard of care). Rate ratio comparing the trial groups will be estimated by fitting a cox regression model. If there are any imbalance in the important participant characteristics at baseline, adjustment for these will be performed by fitting cox regression models. A similar analysis will be performed for the secondary outcomes.
Data quality control:
The study team will be trained on data collection and handling procedures. A pretest in form of completing the study questionnaire as well as a dry run will be done before the commencement of the actual data collection. To ensure proper data management, the data collectors will be trained in data management and will complete certification process of Good Clinical Practices (GCPs). Data collectors will be health workers who work in the Obstetrics department, they will not be directly involved in the management of mothers in Antenatal clinic or inpatient wards to avoid observation bias if he/she was among the people managing these patients. All interviews will be conducted in the language understood by the study participants.
Data monitoring committee:
There will be a data monitoring committee established to monitor the quality of data being collected. This three member committee will be selected from outside the study site. They will be people with experience in monitoring trial data. They will sit every 3 months or as requested by the institutional review board of St. Francis Hospital Nsambya.
Data protection and confidentiality:
The study questionnaires will not bear participant names but rather identification numbers. The study team will ensure the data is not accessible to anyone else by 1) keeping the paper questionnaires under lock and key 2) using passwords to secure the study database. The team will also ensure that the study data is used for only the purpose approved by the ethics committees.
Ethical considerations:
The study will seek ethical approvals from the Institutional Review Board (IRB) of Nsambya Hospital. The Hospital authority will also be requested for permission to have access to the pregnant women in the study clinic. Participants will be allowed to withdraw from the study whenever they so wish. All the data collected will be treated with utmost confidentiality.
STANDARD OPERATING PROCEDURE (SOP) FOR ENROLLMENT/SCREENING VISIT
STANDARD OPERATING PROCEDURE FOR MISSED VISITS
STANDARD OPERATING PROCEDURE FOR TRACING MOTHERS WHO HAVE GONE PAST THEIR EXPECTED DATE OF DELIVERY (EDD) / DELIVERED ELSEWHERE
STANDARD OPERATING PROCEDURE FOR UNSCHEDULED VISIT
STANDARD OPERATING PROCEDURE FOR DOCUMENTING DELIVERY AND FETAL OUTCOME
STANDARD OPERATING PROCEDURE FOR DATA MANAGEMENT
STANDARD OPERATING PROCEDURE FOR COMPLETING CASE REPORT FORM (CRF)
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Modified biophysical profile scan to be done in third trimester for eligible pregnant mothers
Time frame: At delivery of the newborn
Reduction in the proportion of perinatal death will be measured for the two arms of the study to ascertain whether modified biophysical profile can predict perinatal mortality. Perinatal mortality will be measured as death of the new born within the first 7 days of life. The gestational age considered is after 28 weeks of amenorrhea consistent with the health system capacity of the host country and the study hospital
Time frame: at birth
The APGAR score is a clinical score used to assess well being of all newborns. The clinical features of newborn colour, Respiration, Heart rate, muscle tone and reflex stability depends on the aetiology, intensity and duration of oxygen lack, plasma carbondioxide excess and subsequent acidosis. The score will be taken at 1 minute and at 5 minutes after birth and documented in the case report form. Minimum score is 0/10 while the maximum is 10/10. A score of less than 3/10 at 5 minutes indicates severe birth asphyxia; a score of 4/10 to 6/10 signifies moderate asphyxia and 7/10 to 10/10 is a normal new born. The higher the score, the better the neonatal outcome.
Time frame: Immediately after birth
The neonatal intensive care (NICU) admission of the newborn will be documented as yes or no at birth. This will be assessed by documenting the post delivery decision of the attending health worker on whether the baby needs NICU admission or not
Time frame: At delivery
Cesarean section (C/S) performed for fetal conditions will be assessed by the study team by looking out for the indication of C/S and document if it was done due to fetal conditions like non reassuring fetal status, meconium stained liquor, severe oligohydramnios, cord accidents and abnormal fetal heart pattern.
Dr Andrew Odur
Other
Predicting Fetal Outcome Using Third Trimester Modified Biophysical Profile Scan Compared to Standard of Care; an Open Label Randomized Controlled Trial at St. Francis Hospital Nsambya.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06169423
Death, Female Urogenital Diseases and Pregnancy Complications
Castellon, Castellón, Spain
View Trial DetailsNCT04598165
Behavior, Behavioral Symptoms
Ahero, Kisumu County, Kenya
View Trial DetailsNCT05369806
Behavior, Behavioral Symptoms
Ahero, Kisumu County, Kenya
View Trial DetailsNCT03213509
Death, Female Urogenital Diseases and Pregnancy Complications
Shivgarh, Uttar Pradesh, India
View Trial Details